Symptoms timeline and outcomes in amyotrophic lateral sclerosis using artificial intelligence.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
13 01 2023
Historique:
received: 26 04 2022
accepted: 09 01 2023
entrez: 13 1 2023
pubmed: 14 1 2023
medline: 18 1 2023
Statut: epublish

Résumé

Amyotrophic lateral sclerosis (ALS) is a fatal, neurodegenerative motor neuron disease. Although an early diagnosis is crucial to provide adequate care and improve survival, patients with ALS experience a significant diagnostic delay. This study aimed to use real-world data to describe the clinical profile and timing between symptom onset, diagnosis, and relevant outcomes in ALS. Retrospective and multicenter study in 5 representative hospitals and Primary Care services in the SESCAM Healthcare Network (Castilla-La Mancha, Spain). Using Natural Language Processing (NLP), the clinical information in electronic health records of all patients with ALS was extracted between January 2014 and December 2018. From a source population of all individuals attended in the participating hospitals, 250 ALS patients were identified (61.6% male, mean age 64.7 years). Of these, 64% had spinal and 36% bulbar ALS. For most defining symptoms, including dyspnea, dysarthria, dysphagia and fasciculations, the overall diagnostic delay from symptom onset was 11 (6-18) months. Prior to diagnosis, only 38.8% of patients had visited the neurologist. In a median post-diagnosis follow-up of 25 months, 52% underwent gastrostomy, 64% non-invasive ventilation, 16.4% tracheostomy, and 87.6% riluzole treatment; these were more commonly reported (all Ps < 0.05) and showed greater probability of occurrence (all Ps < 0.03) in bulbar ALS. Our results highlight the diagnostic delay in ALS and revealed differences in the clinical characteristics and occurrence of major disease-specific events across ALS subtypes. NLP holds great promise for its application in the wider context of rare neurological diseases.

Identifiants

pubmed: 36639403
doi: 10.1038/s41598-023-27863-2
pii: 10.1038/s41598-023-27863-2
pmc: PMC9839769
doi:

Types de publication

Multicenter Study Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

702

Investigateurs

José Aquino (J)
David Casadevall (D)
David Donaire (D)
Judith Marin-Corral (J)
Sebastian Menke (S)
Natalia Polo (N)

Informations de copyright

© 2023. The Author(s).

Références

PLoS One. 2022 Feb 10;17(2):e0263277
pubmed: 35143527
Amyotroph Lateral Scler Frontotemporal Degener. 2019 Feb;20(1-2):90-99
pubmed: 30430867
Eur Respir J. 2021 Mar 4;57(3):
pubmed: 33154029
J Neurol Sci. 1994 Jul;124 Suppl:96-107
pubmed: 7807156
PLoS One. 2021 Jan 6;16(1):e0244604
pubmed: 33406098
Curr Opin Neurol. 2019 Oct;32(5):771-776
pubmed: 31361627
Amyotroph Lateral Scler Frontotemporal Degener. 2017 Nov;18(7-8):492-497
pubmed: 28457142
Amyotroph Lateral Scler Frontotemporal Degener. 2020 Nov;21(7-8):509-518
pubmed: 32573277
Front Neurosci. 2019 Feb 28;13:135
pubmed: 30872992
J Neurol. 2020 Jul;267(7):2130-2141
pubmed: 32266542
BMC Neurol. 2013 Feb 09;13:19
pubmed: 23394455
Eur J Neurol. 2021 Apr;28(4):1160-1171
pubmed: 33210770
JAMA Oncol. 2017 Oct 01;3(10):1335-1342
pubmed: 28448665
Amyotroph Lateral Scler Frontotemporal Degener. 2018 Nov;19(7-8):522-527
pubmed: 30265157
JAMA Netw Open. 2021 Jul 1;4(7):e2114723
pubmed: 34232304
J Neurol Neurosurg Psychiatry. 1992 Dec;55(12):1116-20
pubmed: 1479388
N Engl J Med. 2001 May 31;344(22):1688-700
pubmed: 11386269
Amyotroph Lateral Scler Other Motor Neuron Disord. 2000 Dec;1(5):293-9
pubmed: 11464847
Aten Primaria. 2021 Dec;53(10):102158
pubmed: 34509895
Drug Saf. 2017 Nov;40(11):1075-1089
pubmed: 28643174
J Neurol. 2017 Jan;264(1):54-63
pubmed: 27778156
J Neurol Sci. 1999 Oct 31;169(1-2):114-7
pubmed: 10540018
Pract Neurol. 2009 Oct;9(5):303-9
pubmed: 19762894
Neurology. 1999;53(8 Suppl 5):S53-4; discussion S55-7
pubmed: 10560640
JMIR Med Inform. 2021 Jul 23;9(7):e20492
pubmed: 34297002
J Neurol Neurosurg Psychiatry. 2019 Apr;90(4):395-403
pubmed: 30409890
JAMA. 2013 Apr 3;309(13):1351-2
pubmed: 23549579
JMIR Med Inform. 2019 Apr 27;7(2):e12239
pubmed: 31066697
Eur J Neurol. 2013 Apr;20(4):647-54
pubmed: 23094606
J Am Med Inform Assoc. 2017 Jan;24(1):198-208
pubmed: 27189013
J Womens Health (Larchmt). 2021 Mar;30(3):393-404
pubmed: 33416429
Eur J Gastroenterol Hepatol. 2022 Apr 1;34(4):389-397
pubmed: 34882644
Cochrane Database Syst Rev. 2002;(2):CD001447
pubmed: 12076411
Nature. 2017 Oct 18;550(7676):S115-S117
pubmed: 29045372
Lancet. 2011 Mar 12;377(9769):942-55
pubmed: 21296405
J Pharm Policy Pract. 2020 Nov 9;13(1):75
pubmed: 33292570
J Neurol Neurosurg Psychiatry. 2010 Oct;81(10):1141-3
pubmed: 20660920
BMC Neurol. 2017 Apr 17;17(1):73
pubmed: 28412941
Front Neurol. 2020 Dec 18;11:604922
pubmed: 33391167
J Neurol Neurosurg Psychiatry. 2007 Jun;78(6):629-31
pubmed: 17088331
Front Neurol. 2021 Oct 27;12:761355
pubmed: 34803894
J Med Internet Res. 2020 Oct 28;22(10):e21801
pubmed: 33090964
Amyotroph Lateral Scler. 2009 Oct-Dec;10(5-6):310-23
pubmed: 19922118
Amyotroph Lateral Scler Frontotemporal Degener. 2018 Nov;19(7-8):528-537
pubmed: 30296856
Neurologia (Engl Ed). 2021 Sep;36(7):504-513
pubmed: 34537164

Auteurs

Tomás Segura (T)

University Hospital of Albacete, Albacete, Spain. tseguram@gmail.com.

Ignacio H Medrano (IH)

Savana Research, Madrid, Spain.

Sergio Collazo (S)

Savana Research, Madrid, Spain.

Claudia Maté (C)

Savana Research, Madrid, Spain.

Carlo Sguera (C)

Savana Research, Madrid, Spain.
UC3M-Santander Big Data Institute, Madrid, Spain.

Carlos Del Rio-Bermudez (C)

Savana Research, Madrid, Spain.

Hugo Casero (H)

Savana Research, Madrid, Spain.

Ignacio Salcedo (I)

Savana Research, Madrid, Spain.

Jorge García-García (J)

University Hospital of Albacete, Albacete, Spain.

Cristian Alcahut-Rodríguez (C)

University Hospital of Albacete, Albacete, Spain.

Miren Taberna (M)

Savana Research, Madrid, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH